Evidence map›Paper›PMID 40050457›Full record

ReviewEuropean radiology2025

Image-guided percutaneous ablative treatments for renal cell carcinoma.

Timo A Auer, Yasmin Uluk, Rosario Francesco Grasso, Roman Kloeckner, Bernhard Gebauer, Thomas Kroencke, Federico Collettini

Abstract readReview
In one paragraph

Review in European radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Timo A AuerDepartment of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany. timo-alexander.auer@charite.de.ORCID http://orcid.org/0000-0002-5763-689X
Yasmin UlukDepartment of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.
Rosario Francesco GrassoDepartment of Radiology, Campus Biomedico University of Rome, Rome, Italy.
Roman KloecknerInstitute of Interventional Radiology, University Hospital Schleswig-Holstein-Campus Lübeck, Lübeck, Germany.
Bernhard GebauerDepartment of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.
Thomas KroenckeDepartment of Diagnostic and Interventional Radiology, University Hospital Augsburg, Augsburg, Germany.
Federico CollettiniDepartment of Radiology, Charité-Universitätsmedizin Berlin, Corporate Member of Freie Universität and Humboldt-Universität zu Berlin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In recent decades, percutaneous ablation procedures have evolved into a recognized treatment option for renal cell carcinoma (RCC). Thermal ablation techniques, including radiofrequency ablation (RFA), microwave ablation (MWA), and cryoablation (CA) are now incorporated in most treatment guidelines as a viable alternative, and in some cases, deemed equivalent to nephron-sparing surgery (NSS) or other surgical methods, especially for small renal masses (SRM) up to 4 cm. This review offers an overview of the most prevalent ablation techniques used to treat localized RCC. Additionally, it compares the oncological and clinical outcomes of these techniques with those of surgical options. Finally, it provides an assessment of the role that ablation treatment occupies in current guidelines. In conclusion, the use and incorporation of image-guided minimally invasive treatment options for RCC is on the rise. Existing data suggest that thermal ablation procedures (RFA, MWA, and CA) and partial nephrectomy yield comparable oncologic and clinical outcomes. Despite the data available, the recommendations for thermal ablations vary significantly across national and international guidelines. KEY POINTS: Question Despite growing evidence and integration in international guidelines, recommendations for ablative procedures in localized small renal cell cancer vary considerably. Findings Existing, mostly retrospective, data suggest that thermal ablation and partial nephrectomy yield comparable clinical results for small tumors. Clinical relevance Based on the current literature, thermal ablation of renal cell cancer up to 4 cm in size can be offered to patients as an alternative to surgery.

Indexed as

Ablation TechniquesCarcinoma, Renal CellCatheter AblationKidney NeoplasmsSurgery, Computer-AssistedCryosurgeryHumansMicrowavesNephrectomyRadiofrequency AblationTreatment OutcomeCryoablationMicrowave ablationPartial nephrectomyRadiofrequency AblationRenal cell carcinoma

Identifiers

PMID40050457
PMCPMC12350574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.